Principal Financial Group
AXSM icon

Principal Financial Group’s Axsome Therapeutics AXSM Stock Holding History

Principal Financial Group’s Portfolio AXSM Stock Details AXSM Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q3 		$57.2M Sell
310,080
-22,562
-7% -$4.91M 0.03% 429
2026
Q2 		$81.4M Sell
332,642
-17,846
-5% -$3.87M 0.04% 364
2026
Q1 		$59.2M Sell
350,488
-12,626
-3% -$2.18M 0.03% 438
2025
Q4 		$66.3M Sell
363,114
-5,320
-1% -$743K 0.03% 385
2025
Q3 		$44.7M Buy
368,434
+12,923
+4% +$1.46M 0.02% 504
2025
Q2 		$37.1M Buy
355,511
+59,840
+20% +$6.34M 0.02% 557
2025
Q1 		$34.5M Buy
295,671
+88,606
+43% +$10.1M 0.02% 554
2024
Q4 		$17.5M Buy
207,065
+203,672
+6,003% +$18.7M 0.01% 938
2024
Q3 		$305K Sell
3,393
-3,161
-48% -$276K ﹤0.01% 2026
2024
Q2 		$528K Sell
6,554
-3,219
-33% -$238K ﹤0.01% 1940
2024
Q1 		$780K Buy
9,773
+276
+3% +$23.2K ﹤0.01% 1903
2023
Q4 		$756K Buy
9,497
+120
+1% +$8.02K ﹤0.01% 1878
2023
Q3 		$655K Sell
9,377
-34,164
-78% -$2.55M ﹤0.01% 1902
2023
Q2 		$3.13M Buy
43,541
+33,821
+348% +$2.49M ﹤0.01% 1677
2023
Q1 		$600K Sell
9,720
-608
-6% -$39.9K ﹤0.01% 1932
2022
Q4 		$797K Buy
10,328
+1,694
+20% +$101K ﹤0.01% 1892
2022
Q3 		$385K Sell
8,634
-52
-0.6% -$2.6K ﹤0.01% 2016
2022
Q2 		$333K Buy
8,686
+3,598
+71% +$114K ﹤0.01% 2155
2022
Q1 		$211K Buy
+5,088
New +$158K ﹤0.01% 2325
2021
Q4 		– Sell
-7,418
Closed -$244K – 2541
2021
Q3 		$244K Sell
7,418
-5,646
-43% -$220K ﹤0.01% 2376
2021
Q2 		$882K Sell
13,064
-1,131
-8% -$67.9K ﹤0.01% 2071
2021
Q1 		$804K Sell
14,195
-522
-4% -$36.7K ﹤0.01% 2040
2020
Q4 		$1.2M Buy
14,717
+3,198
+28% +$239K ﹤0.01% 1905
2020
Q3 		$820K Sell
11,519
-527
-4% -$41.1K ﹤0.01% 1911
2020
Q2 		$991K Buy
12,046
+6,678
+124% +$514K ﹤0.01% 1832
2020
Q1 		$316K Sell
5,368
-2,157
-29% -$176K ﹤0.01% 1948
2019
Q4 		$777K Buy
+7,525
New +$304K ﹤0.01% 1872

Other funds holding AXSM

Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.92T AUM 36.1% 1-Year Est. Return
Pictet Asset Management
Pictet Asset Management Carouge, Switzerland $106B AUM 32.76% 1-Year Est. Return
Assenagon Asset Management
Assenagon Asset Management Senningerberg, Luxembourg $103B AUM 40.17% 1-Year Est. Return
Bank of New York Mellon
Bank of New York Mellon New York $608B AUM 32.77% 1-Year Est. Return
Deutsche Bank
Deutsche Bank Frankfurt Am Main Ge, Germany $362B AUM 34.89% 1-Year Est. Return
Aberdeen Group
Aberdeen Group Edinburgh, United Kingdom $72.4B AUM 24.61% 1-Year Est. Return
Amundi
Amundi Paris, France $496B AUM 35.36% 1-Year Est. Return
US Bancorp
US Bancorp Minneapolis, Minnesota $92B AUM 22.91% 1-Year Est. Return
Allspring Global Investments
Allspring Global Investments Charlotte, North Carolina $64.1B AUM 28.9% 1-Year Est. Return
TimesSquare Capital Management
TimesSquare Capital Management New York $6.12B AUM 30.01% 1-Year Est. Return

Principal Financial Group's AXSM Position: Q3 2026 in Review

Principal Financial Group reduced its Axsome Therapeutics (AXSM) stake by 6.8% in Q3 2026, selling an estimated $4.91M and leaving 310,080 shares worth $57.2M. The position accounts for 0.03% of the portfolio, ranked #429.

Principal Financial Group first reported a position in AXSM in Q4 2019 and has held it in 27 quarters since. The position peaked at $81.4M in Q2 2026. 185 funds tracked by Wall St. Rank hold AXSM as of Q3 2026.

  • Principal Financial Group held 310,080 shares of Axsome Therapeutics worth $57.2M as of Q3 2026.
  • Principal Financial Group sold 22,562 Axsome Therapeutics shares in Q3 2026, an estimated $4.91M.
  • Axsome Therapeutics made up 0.03% of Principal Financial Group's portfolio in Q3 2026, its #429 holding.
  • Principal Financial Group first reported a position in Axsome Therapeutics in Q4 2019 and has held it in 27 quarters since.
  • Principal Financial Group's Axsome Therapeutics position peaked at $81.4M in Q2 2026.
  • 185 funds tracked by Wall St. Rank held Axsome Therapeutics as of Q3 2026.

Based on Principal Financial Group's 13F filing for Q3 2026, filed 2 Nov 2026.